Soleno wakes up to a securities lawsuit

Another day, another courtroom cameo

Soleno Therapeutics just got slapped with a securities fraud class action, and the allegation is pretty classic corporate-drama material: investors say the company made misleading statements about its Phase 3 clinical trial program for DCCR.

For shareholders, this is the annoying part of biotech ownership. You’re not just betting on the science — you’re also betting that the company’s story survives contact with reality, and sometimes the lawyers show up to check the receipts.

Why this matters to investors

The complaint covers investors who bought Soleno common stock between March 26, 2025 and August 4, 2025. If the case gains traction, it can mean:

• legal expenses that eat into the company’s runway
• extra volatility as headline risk hangs over the stock
• more scrutiny around disclosures, trial updates, and management credibility

Big picture

This doesn’t automatically mean Soleno did anything wrong, but it does mean the market has a fresh excuse to focus on risk instead of just the pipeline. In biotech, that can be half the battle.